Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.
Infectious DiseasesCentral Nervous System (CNS) Diseases
Technology Platform
A therapeutic modality-agnostic development and commercialization engine focused on in-licensing and co-developing clinical-stage assets, with a thematic expertise in long-acting injectable biologics and antibodies.
Funding History
2
Total raised:$455M
Series C$300MTemasek Holdings
Series B$155MHillhouse Capital
Opportunities
The massive, underserved Chronic Hepatitis B market in Asia represents a multi-billion dollar opportunity for a functional cure regimen.
Successfully leveraging its established commercial and regulatory bridge to China could accelerate the launch of future pipeline products in one of the world's largest pharmaceutical markets.
Risk Factors
High dependency on the success of a few key clinical programs, particularly the HBV combination.
The business model is exposed to geopolitical tensions and regulatory shifts between the US and China.
Revenue from the commercial COVID-19 antibody is likely variable and may decline.
Competitive Landscape
Faces intense competition in Hepatitis B from large pharma and biotechs pursuing various functional cure modalities. In PPD, must differentiate against newly approved oral therapies. Its primary competitive advantage is its validated capability to develop and commercialize products specifically for the Chinese market.
